NASDAQ:CYTK

Cytokinetics Competitors

$24.70

-0.17 (-0.68 %)

(As of 04/16/2021 12:00 AM ET)

Add

Compare

Today's Range

$23.68

Now: $24.70▼

$24.78

50-Day Range

$18.57

MA: $22.61▼

$25.68

52-Week Range

$13.45

Now: $24.70▼

$30.14

Volume573,796 shs

Average Volume920,504 shs

Market Capitalization$1.77 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.45

Cytokinetics (NASDAQ:CYTK) Vs. ARWR, GWPH, ASND, TGTX, IONS, and SRPT

Should you be buying CYTK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cytokinetics, including Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals (GWPH), Ascendis Pharma A/S (ASND), TG Therapeutics (TGTX), Ionis Pharmaceuticals (IONS), and Sarepta Therapeutics (SRPT).

Cytokinetics vs. Arrowhead Pharmaceuticals Stock

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

Insider & Institutional Ownership

65.5% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 4.0% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Arrowhead Pharmaceuticals and Cytokinetics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-96.09%	-17.37%	-15.19%
Cytokinetics	-209.88%	-3,065.14%	-36.39%

Valuation & Earnings

This table compares Arrowhead Pharmaceuticals and Cytokinetics' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$87.99 million	79.80	$-84,550,000.00	($0.84)	-80.54
Cytokinetics	$26.87 million	65.76	$-121,690,000.00	($2.11)	-11.71

Arrowhead Pharmaceuticals has higher revenue and earnings than Cytokinetics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Arrowhead Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Arrowhead Pharmaceuticals and Cytokinetics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	0	2	10	0	2.83
Cytokinetics	0	1	10	0	2.91

Arrowhead Pharmaceuticals currently has a consensus target price of $85.3077, suggesting a potential upside of 26.10%. Cytokinetics has a consensus target price of $33.6364, suggesting a potential upside of 36.18%. Given Cytokinetics' stronger consensus rating and higher possible upside, analysts clearly believe Cytokinetics is more favorable than Arrowhead Pharmaceuticals.

Summary

Arrowhead Pharmaceuticals beats Cytokinetics on 8 of the 13 factors compared between the two stocks.

Cytokinetics vs. GW Pharmaceuticals Stock

Cytokinetics (NASDAQ:CYTK) and GW Pharmaceuticals (NASDAQ:GWPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

97.1% of Cytokinetics shares are held by institutional investors. Comparatively, 81.0% of GW Pharmaceuticals shares are held by institutional investors. 6.4% of Cytokinetics shares are held by insiders. Comparatively, 3.1% of GW Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cytokinetics and GW Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0	1	10	0	2.91
GW Pharmaceuticals	0	10	4	0	2.29

Cytokinetics presently has a consensus target price of $33.6364, suggesting a potential upside of 36.18%. GW Pharmaceuticals has a consensus target price of $204.0909, suggesting a potential downside of 6.77%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cytokinetics is more favorable than GW Pharmaceuticals.

Risk & Volatility

Cytokinetics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, GW Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Profitability

This table compares Cytokinetics and GW Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-209.88%	-3,065.14%	-36.39%
GW Pharmaceuticals	-11.05%	-7.46%	-6.13%

Earnings & Valuation

This table compares Cytokinetics and GW Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$26.87 million	65.76	$-121,690,000.00	($2.11)	-11.71
GW Pharmaceuticals	$311.33 million	22.04	$-9,020,000.00	($0.24)	-912.08

GW Pharmaceuticals has higher revenue and earnings than Cytokinetics. GW Pharmaceuticals is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Cytokinetics vs. Ascendis Pharma A/S Stock

Cytokinetics (NASDAQ:CYTK) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

97.1% of Cytokinetics shares are held by institutional investors. 6.4% of Cytokinetics shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cytokinetics and Ascendis Pharma A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0	1	10	0	2.91
Ascendis Pharma A/S	0	1	11	0	2.92

Cytokinetics presently has a consensus target price of $33.6364, suggesting a potential upside of 36.18%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 53.89%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Cytokinetics.

Risk & Volatility

Cytokinetics has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Profitability

This table compares Cytokinetics and Ascendis Pharma A/S's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-209.88%	-3,065.14%	-36.39%
Ascendis Pharma A/S	-4,042.79%	-55.72%	-49.42%

Earnings & Valuation

This table compares Cytokinetics and Ascendis Pharma A/S's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$26.87 million	65.76	$-121,690,000.00	($2.11)	-11.71
Ascendis Pharma A/S	$14.98 million	437.57	$-244,180,000.00	($5.25)	-23.23

Cytokinetics has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Summary

Cytokinetics beats Ascendis Pharma A/S on 8 of the 14 factors compared between the two stocks.

Cytokinetics vs. TG Therapeutics Stock

Cytokinetics (NASDAQ:CYTK) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cytokinetics and TG Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-209.88%	-3,065.14%	-36.39%
TG Therapeutics	-151,798.69%	-223.96%	-108.08%

Valuation & Earnings

This table compares Cytokinetics and TG Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$26.87 million	65.76	$-121,690,000.00	($2.11)	-11.71
TG Therapeutics	$150,000.00	41,969.61	$-172,870,000.00	($1.83)	-24.47

Cytokinetics has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, TG Therapeutics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500.

Institutional and Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 65.7% of TG Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by insiders. Comparatively, 13.2% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cytokinetics and TG Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0	1	10	0	2.91
TG Therapeutics	0	0	5	0	3.00

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. TG Therapeutics has a consensus price target of $64.00, suggesting a potential upside of 42.92%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Cytokinetics.

Cytokinetics vs. Ionis Pharmaceuticals Stock

Cytokinetics (NASDAQ:CYTK) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cytokinetics and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-209.88%	-3,065.14%	-36.39%
Ionis Pharmaceuticals	7.82%	6.57%	3.39%

Valuation & Earnings

This table compares Cytokinetics and Ionis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$26.87 million	65.76	$-121,690,000.00	($2.11)	-11.71
Ionis Pharmaceuticals	$1.12 billion	5.12	$303.26 million	$2.08	19.61

Ionis Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500.

Institutional and Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 84.1% of Ionis Pharmaceuticals shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cytokinetics and Ionis Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0	1	10	0	2.91
Ionis Pharmaceuticals	2	7	6	0	2.27

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. Ionis Pharmaceuticals has a consensus price target of $57.9091, suggesting a potential upside of 42.00%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Cytokinetics.

Summary

Ionis Pharmaceuticals beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

Cytokinetics vs. Sarepta Therapeutics Stock

Cytokinetics (NASDAQ:CYTK) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cytokinetics and Sarepta Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-209.88%	-3,065.14%	-36.39%
Sarepta Therapeutics	-121.30%	-61.62%	-23.02%

Valuation & Earnings

This table compares Cytokinetics and Sarepta Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$26.87 million	65.76	$-121,690,000.00	($2.11)	-11.71
Sarepta Therapeutics	$380.83 million	14.97	$-715,080,000.00	($9.71)	-7.39

Cytokinetics has higher earnings, but lower revenue than Sarepta Therapeutics. Cytokinetics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cytokinetics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Institutional and Insider Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 89.7% of Sarepta Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by insiders. Comparatively, 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cytokinetics and Sarepta Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	0	1	10	0	2.91
Sarepta Therapeutics	1	9	13	0	2.52

Cytokinetics presently has a consensus price target of $33.6364, suggesting a potential upside of 36.18%. Sarepta Therapeutics has a consensus price target of $150.4762, suggesting a potential upside of 109.58%. Given Sarepta Therapeutics' higher possible upside, analysts plainly believe Sarepta Therapeutics is more favorable than Cytokinetics.

Summary

Sarepta Therapeutics beats Cytokinetics on 8 of the 14 factors compared between the two stocks.